290 related articles for article (PubMed ID: 28825178)
1. Ovarian cancer recurrence and early detection: may HE4 play a key role in this open challenge? A systematic review of literature.
Capriglione S; Luvero D; Plotti F; Terranova C; Montera R; Scaletta G; Schirò T; Rossini G; Benedetti Panici P; Angioli R
Med Oncol; 2017 Aug; 34(9):164. PubMed ID: 28825178
[TBL] [Abstract][Full Text] [Related]
2. Does Human Epididymis Protein 4 (HE4) Have a Role in Prediction of Recurrent Epithelial Ovarian Cancer.
Innao P; Pothisuwan M; Pengsa P
Asian Pac J Cancer Prev; 2016; 17(9):4483-4486. PubMed ID: 27797265
[TBL] [Abstract][Full Text] [Related]
3. Evaluation of HE4, CA125, risk of ovarian malignancy algorithm (ROMA) and risk of malignancy index (RMI) as diagnostic tools of epithelial ovarian cancer in patients with a pelvic mass.
Karlsen MA; Sandhu N; Høgdall C; Christensen IJ; Nedergaard L; Lundvall L; Engelholm SA; Pedersen AT; Hartwell D; Lydolph M; Laursen IA; Høgdall EV
Gynecol Oncol; 2012 Nov; 127(2):379-83. PubMed ID: 22835718
[TBL] [Abstract][Full Text] [Related]
4. Prognostic value of serum and tissue HE4 expression in ovarian cancer: a systematic review with meta-analysis of 90 studies.
Cao H; You D; Lan Z; Ye H; Hou M; Xi M
Expert Rev Mol Diagn; 2018 Apr; 18(4):371-383. PubMed ID: 29569984
[TBL] [Abstract][Full Text] [Related]
5. The role of human epididymis protein 4 in the diagnosis of epithelial ovarian cancer.
Jia LT; Zhang YC; Li J; Tian Y; Li JF
Clin Transl Oncol; 2016 Mar; 18(3):233-9. PubMed ID: 26220095
[TBL] [Abstract][Full Text] [Related]
6. Accuracy of serum human epididymis protein 4 in ovarian cancer diagnosis: a systematic review and meta-analysis.
Macedo AC; da Rosa MI; Lumertz S; Medeiros LR
Int J Gynecol Cancer; 2014 Sep; 24(7):1222-31. PubMed ID: 25078339
[TBL] [Abstract][Full Text] [Related]
7. Diagnostic Performance of Risk of Ovarian Malignancy Algorithm Against CA125 and HE4 in Connection With Ovarian Cancer: A Meta-analysis.
Dayyani F; Uhlig S; Colson B; Simon K; Rolny V; Morgenstern D; Schlumbrecht M
Int J Gynecol Cancer; 2016 Nov; 26(9):1586-1593. PubMed ID: 27540691
[TBL] [Abstract][Full Text] [Related]
8. The role of HE4 for prediction of recurrence in epithelial ovarian cancer patients-results from the OVCAD study.
Nassir M; Guan J; Luketina H; Siepmann T; Rohr I; Richter R; Castillo-Tong DC; Zeillinger R; Vergote I; Van Nieuwenhuysen E; Concin N; Marth C; Hall C; Mahner S; Woelber L; Sehouli J; Braicu EI
Tumour Biol; 2016 Mar; 37(3):3009-16. PubMed ID: 26419591
[TBL] [Abstract][Full Text] [Related]
9. Role of human epididymis protein 4 in chemoresistance and prognosis of epithelial ovarian cancer.
Lee S; Choi S; Lee Y; Chung D; Hong S; Park N
J Obstet Gynaecol Res; 2017 Jan; 43(1):220-227. PubMed ID: 27862665
[TBL] [Abstract][Full Text] [Related]
10. The role of human epididymis protein 4 as a biomarker in gynecologic malignancies.
Plotti F; Scaletta G; Terranova C; Montera R; De Cicco Nardone C; Luvero D; Rossini G; Gatti A; Schirò T; Moncelli M; Guzzo F; Angioli R
Minerva Ginecol; 2019 Feb; 71(1):36-43. PubMed ID: 30318876
[TBL] [Abstract][Full Text] [Related]
11. M-CSF in a new biomarker panel with HE4 and CA 125 in the diagnostics of epithelial ovarian cancer patients.
Będkowska GE; Ławicki S; Gacuta E; Pawłowski P; Szmitkowski M
J Ovarian Res; 2015 May; 8():27. PubMed ID: 25935153
[TBL] [Abstract][Full Text] [Related]
12. [Expression of serum human epididymis protein 4 in epithelial ovarian cancer and its correlation with prognosis].
Zheng H; Gao YN; Gao WJ; Gao M; Yan X
Zhonghua Zhong Liu Za Zhi; 2013 Jun; 35(6):445-9. PubMed ID: 24119905
[TBL] [Abstract][Full Text] [Related]
13. HE4 as an Early Detection Biomarker of Epithelial Ovarian Cancer: Investigations in Prediagnostic Specimens From the Janus Serumbank.
Gislefoss RE; Langseth H; Bolstad N; Nustad K; Mørkrid L
Int J Gynecol Cancer; 2015 Nov; 25(9):1608-15. PubMed ID: 26501436
[TBL] [Abstract][Full Text] [Related]
14. The role of HE4 in ovarian cancer follow-up: a review.
Piovano E; Attamante L; Macchi C; Cavallero C; Romagnolo C; Maggino T; Landoni F; Gadducci A; Sartori E; Gion M; Zola P
Int J Gynecol Cancer; 2014 Oct; 24(8):1359-65. PubMed ID: 25054447
[TBL] [Abstract][Full Text] [Related]
15. The role of novel biomarker HE4 in the diagnosis, prognosis and follow-up of ovarian cancer: a systematic review.
Scaletta G; Plotti F; Luvero D; Capriglione S; Montera R; Miranda A; Lopez S; Terranova C; De Cicco Nardone C; Angioli R
Expert Rev Anticancer Ther; 2017 Sep; 17(9):827-839. PubMed ID: 28756722
[TBL] [Abstract][Full Text] [Related]
16. Recent Insight about HE4 Role in Ovarian Cancer Oncogenesis.
Anastasi E; Farina A; Granato T; Colaiacovo F; Pucci B; Tartaglione S; Angeloni A
Int J Mol Sci; 2023 Jun; 24(13):. PubMed ID: 37445657
[TBL] [Abstract][Full Text] [Related]
17. Is HE4 Superior over CA-125 in the Follow-up of Patients with Epithelial Ovarian Cancer?
El Bairi K; Afqir S; Amrani M
Curr Drug Targets; 2020; 21(10):1026-1033. PubMed ID: 32334501
[TBL] [Abstract][Full Text] [Related]
18. Clinical value of human epididymis protein 4 and the Risk of Ovarian Malignancy Algorithm in differentiating borderline pelvic tumors from epithelial ovarian cancer in early stages.
Kotowicz B; Fuksiewicz M; Sobiczewski P; Spiewankiewicz B; Jonska-Gmyrek J; Skrzypczak M; Kowalska M
Eur J Obstet Gynecol Reprod Biol; 2015 Nov; 194():141-6. PubMed ID: 26398337
[TBL] [Abstract][Full Text] [Related]
19. Serum HE4 levels combined with CE CT imaging improve the management of monitoring women affected by epithelial ovarian cancer.
Manganaro L; Michienzi S; Vinci V; Falzarano R; Saldari M; Granato T; Viggiani V; Frati L; Anastasi E
Oncol Rep; 2013 Nov; 30(5):2481-7. PubMed ID: 23970060
[TBL] [Abstract][Full Text] [Related]
20. HE4, CA125 and risk of ovarian malignancy algorithm (ROMA) as diagnostic tools for ovarian cancer in patients with a pelvic mass: An Italian multicenter study.
Romagnolo C; Leon AE; Fabricio ASC; Taborelli M; Polesel J; Del Pup L; Steffan A; Cervo S; Ravaggi A; Zanotti L; Bandiera E; Odicino FE; Scattolo N; Squarcina E; Papadakis C; Maggino T; Gion M
Gynecol Oncol; 2016 May; 141(2):303-311. PubMed ID: 26801941
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
